Sunday 01 October 2023 - 14:01
In Business 43 Years - Since 1980
NOTE: our usual phone and fax lines are down, due to a dispute between our landlord and Verizon.
In the meantime, please use this mobile phone number: 978-715-9327 and this fax number:
The 25% Discount for Shopping Cart Purchases is now PERMANENT !!
For Online Shopping Cart Orders Only
In-Stock Sizes Only
See Check-out Page For Further Details
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
Search:
D-3608 Dovitinib, Free Base, >99%
Synonyms : [CHIR-258] [TKI-258]
- Size
- US $
- €
- £
- ¥
- 10 mg
- 73
- 68
- 59
- 10,900
- In stock
- 25 mg
- 144
- 136
- 118
- 21,500
- In stock
- 50 mg
- 213
- 201
- 174
- 31,800
- In stock
- 100 mg
- 356
- 336
- 291
- 53,200
- In stock
- 200 mg
- 632
- 597
- 518
- 94,400
- In stock
- 500 mg
- 1,080
- 1,020
- 885
- 161,300
- In stock
- 1 g
- 1,770
- 1,672
- 1,451
- 264,400
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities
Free Shipping and Handling to the U.S. and 32 Other Countries
- M.W. 392.43
- C21H21FN6O
- [405169-16-6]
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO. Disposal: A.
- This research compound is the free base form of dovitinib. We also offer the lactate salt form of dovitinib: Cat. No. D-3699, Dovitinib, Lactate Salt.
- This dovitinib product is the free base whose CAS number is given above. The CAS number of the lactate salt form is 692737-80-7
- Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
